×
About 2,713 results

ALLMedicine™ Chronic Cough Center

Research & Reviews  871 results

Demographic, Clinical, and Patient-Reported Outcome Data From Two Global, Phase 3 Trial...
https://doi.org/10.1016/j.anai.2022.05.003
Annals of Allergy, Asthma & Immunology : Official Publica... Dicpinigaitis PV, Birring SS et. al.

May 16th, 2022 - Current characterization of patients with refractory or unexplained chronic cough (RCC and UCC, respectively) primarily stems from relatively small clinical studies. To report the baseline medical history and clinical characteristics of individual...

A 68-Year-Old Woman With Refractory Cough and Insidious Tracheal Thickening.
https://doi.org/10.1016/j.chest.2022.01.012
Chest Serajeddini H, Shargall Y et. al.

May 9th, 2022 - A 68-year-old woman presented to a subspecialty complex-airways-disease clinic with chronic cough. She had a 10-pack-year history of smoking, quit over 35 years ago, and had mild atopy (dust mite) and mild rhinitis. She did not have any relevant o...

Chronic cough in asthma is associated with increased airway inflammation, more comorbid...
https://doi.org/10.2500/aap.2022.43.220022
Allergy and Asthma Proceedings; Deng SJ, Wang J et. al.

May 8th, 2022 - Background: Cough is often the most prominent and intractable symptom reported by patients with asthma, but few studies have explored the characteristics of patients with asthma and with chronic cough (CC) in a real-world setting. Methods: In a pr...

Clinical Formulation Bridging of Gefapixant, a P2X3-Receptor Antagonist, for the Treatm...
https://doi.org/10.1002/cpdd.1105
Clinical Pharmacology in Drug Development; Gupta P, Hussain A et. al.

May 6th, 2022 - Gefapixant is a P2X3-receptor antagonist being developed for treatment of refractory or unexplained chronic cough. Four phase 1 studies were conducted in healthy participants that bridged the early-phase gefapixant formulation (F01) to the phase 3...

Patient-Reported Qualitative Analysis of Chronic Refractory Cough.
https://doi.org/10.1044/2022_AJSLP-21-00364
American Journal of Speech-language Pathology; Wright ML, Fujiki RB et. al.

May 6th, 2022 - Chronic cough has been shown to be associated with adverse effects on quality of life. There is a paucity of research characterizing quality-of-life factors associated with chronic refractory cough (CRC), a cough persisting > 8 weeks despite evalu...

see more →

Guidelines  9 results

ACR Appropriateness Criteria® Chronic Cough.
https://doi.org/10.1016/j.jacr.2021.08.007
Journal of the American College of Radiology : JACR; , Kuzniewski CT et. al.

Nov 20th, 2021 - Chronic cough is defined by a duration lasting at least 8 weeks. The most common causes of chronic cough include smoking-related lung disease, upper airway cough syndrome, asthma, gastroesophageal reflux disease, and nonasthmatic eosinophilic bron...

Managing Chronic Cough as a Symptom in Children and Management Algorithms: CHEST Guidel...
https://doi.org/10.1016/j.chest.2020.01.042
Chest Chang AB, Oppenheimer JJ et. al.

Mar 18th, 2020 - Cough is one of the most common presenting symptoms to general practitioners. The objective of this article is to collate the pediatric components of the CHEST chronic cough guidelines that have recently updated the 2006 guidelines to assist gener...

Chronic Cough Due to Stable Chronic Bronchitis: CHEST Expert Panel Report.
https://doi.org/10.1016/j.chest.2020.02.015
Chest Malesker MA, Callahan-Lyon P et. al.

Feb 28th, 2020 - Chronic cough due to chronic bronchitis (CB) causes significant impairment in quality of life, and effective treatment strategies are needed. We conducted a systematic review on the management of chronic cough due to CB to update the recommendatio...

Acute Cough Due to Acute Bronchitis in Immunocompetent Adult Outpatients: CHEST Expert ...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8173775
Chest Smith MP, Lown M et. al.

Feb 25th, 2020 - Evidence for the diagnosis and management of cough due to acute bronchitis in immunocompetent adult outpatients was reviewed as an update to the 2006 "Chronic Cough Due to Acute Bronchitis: American College of Chest Physicians (ACCP) Evidence-Base...

Managing Chronic Cough Due to Asthma and NAEB in Adults and Adolescents: CHEST Guidelin...
https://doi.org/10.1016/j.chest.2019.12.021
Chest Côté A, Russell RJ et. al.

Jan 24th, 2020 - Asthma and non-asthmatic eosinophilic bronchitis (NAEB) are among the commonest causes of chronic cough in adults. We sought to determine the role of non-invasive measurements of airway inflammation, including induced sputum and fractional exhaled...

see more →

Drugs  36 results see all →

Clinicaltrials.gov  67 results

Study on the Safety of BAY1817080 How it is Tolerated and the Way the Body Absorbs, Distributes and Gets Rid of the Study Drug Given to Participants With Moderate Renal Impairment and End Stage Ren...
https://clinicaltrials.gov/ct2/show/NCT04471337

May 3rd, 2022 - BAY1817080 is currently under clinical development to treat pain related to unexplained chronic cough or chronic cough not affected by a treatment (refractory and/or unexplained chronic cough, RUCC), or a condition where the bladder is unable to h...

Evaluation of the Diagnostic Value of Video-oculography in CANVAS Neuronopathies
https://clinicaltrials.gov/ct2/show/NCT05278091

Apr 22nd, 2022 - Cerebellar ataxia syndrome with neuropathy and vestibular areflexia (CANVAS) is a genetic pathology of recent discovery (bi-allelic expansion in intron 1 of the RFC1 gene with AAGG repetition). The clinical picture is protean, associating a neuron...

Lexiva for the Treatment of LPR
https://clinicaltrials.gov/ct2/show/NCT04383262

Apr 5th, 2022 - Laryngopharyngeal reflux (LPR) causes chronic cough, throat clearing, hoarseness, and dysphagia and if left untreated can promote the development of laryngeal cancer. More than 20% of the United Stated population suffer from LPR, yet there is no e...

Efficacy and Safety Study of Orvepitant for Chronic Cough in Patients With Idiopathic Pulmonary Fibrosis
https://clinicaltrials.gov/ct2/show/NCT05185089

Mar 31st, 2022 - The study will be a multi-center, double-blind, randomised, placebo-controlled 2-period cross-over study in subjects with chronic cough due to idiopathic pulmonary fibrosis (IPF). Subjects will participate in one of two cohorts (Cohort 1 and Cohor...

Assessment of an Exhaled Breath Test to Detect Bronchiectasis
https://clinicaltrials.gov/ct2/show/NCT05293314

Mar 31st, 2022 - Bronchiectasis is a chronic airway inflammation with irreversible expansion of bronchial walls, which is characteristic by chronic cough, mucinous sputum, dyspnea and wheezing. High resolution CT (HRCT) combined with clinical manifestations is the...

see more →

News  95 results

COPD Screening for Asymptomatic Adults? USPSTF Weighs In, Again
https://www.medscape.com/viewarticle/973787

May 11th, 2022 - Screening for chronic obstructive pulmonary disease (COPD) in asymptomatic adults has no net benefit, according to a U.S. Preventive Services Task Force (USPSTF) reassessment of its 2016 screening recommendations. The new recommendation is in line...

Cough-Specific QOL Linked to Poor Outcomes in ILD Patients
https://www.medscape.com/viewarticle/972378

Apr 19th, 2022 - Poor cough-specific quality of life (QOL) was independently associated with respiratory hospitalization, death, and lung transplantation in a large population of well-characterized patients with interstitial lung disease (ILD), new research shows....

Fast Five Quiz: Idiopathic Pulmonary Fibrosis
https://www.medscape.com/viewarticle/925452

Apr 18th, 2022 - Idiopathic pulmonary fibrosis (IPF) is a devastating chronic lung disease of unknown cause characterized by progressive lung scarring. Affecting approximately 3 million people worldwide, IPF is the most common form of idiopathic interstitial pneum...

Fast Five Quiz: Idiopathic Pulmonary Fibrosis
https://reference.medscape.com/viewarticle/925452

Apr 18th, 2022 - Idiopathic pulmonary fibrosis (IPF) is a devastating chronic lung disease of unknown cause characterized by progressive lung scarring. Affecting approximately 3 million people worldwide, IPF is the most common form of idiopathic interstitial pneum...

FDA, DEA Pushed to Make Gabapentin a Controlled Substance to Stop 'Widespread Misuse'
https://www.medscape.com/viewarticle/969829

Mar 7th, 2022 - In a bid to stop abuse and diversion of the anticonvulsant gabapentin, a watchdog group is petitioning federal regulators to make the drug a controlled substance. The nonprofit group Public Citizen has filed a petition with the US Food and Drug Ad...

see more →

Patient Education  7 results see all →